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According to the World Health Organization (WHO), on tropical and 
subtropical areas, schistosomiasis is the second parasitic disease of greater 
prevalence, in terms of morbidity and mortality, surpassed only by malaria. 
The Praziquantel (PZQ) is used for the treatment of this disease. However, 
reports of resistant strains reinforce the need to develop a new 
schistosomicidal drug. The infection by the parasite induces an inflammatory 
reaction of long duration due to the presence of adult worms living in the 
mesenteric venous system. The parasite lays eggs in small vessels of the 
submucosa of the intestines. These eggs are transported by the blood flow to 
the liver and they cause a granulomatous inflammatory reaction. A new 
approach can be held by the study of the following Schistosoma mansoni 
enzymes: purine nucleoside phosphorilase 1 (PNP), hypoxanthine guanine 
phosphoribosyltransferase (HGPRT) and adenylate kinase (ADK). The 
parasite, incapable of synthetizing purine nucleotides through the de novo 
pathway, has multiple mechanisms to incorporate purine bases through the 
purine salvage pathway. In our results, we suggest that the immunization in 
Balb/c mice with the mentioned recombinant enzymes was capable of 
inducing a specific immune response, favoring the reduction of both the 
parasite load and number of eggs per gram of feces. The acquired data show 
that these enzymes can be considered as new targets to immunotherapy 
against schistosomiasis mansoni.    
 
                   Copy Right, IJAR, 2013,. All rights reserved.
 
1. Introduction  
 
 
According to the World Health Organization (WHO), schistosomiasis is the second most predominant parasitic 
disease in tropical and subtropical areas; it is only surpassed by malaria when we compare the morbidity and 
mortality rates of these two diseases. About 779 million people of 77 endemic countries live in the areas where the 
risk of contamination is high (WHO, 2012). This disease is caused by a trematode of the Schistosoma genus which 
affects mainly the populations in developing countries (Hotez & Ferriz, 2006). The World Health Organization 
recommends the use of Praziquantel (PZQ) to treat the schistosomiasis; however, this medicine leads to some 
mutagenic and teratogenic side effects, and in the last 30 years, no new drugs have been developed to deal with this 
disease (Novaes et al., 1999; Shu-hua, 2005). The S. mansoni is a complex organism; it has specific antigens in each 
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phase of its development: cercariae, schistosomula, adult worms and eggs. The infection by the parasite induces an 
inflammatory reaction of long duration due to the presence of adult worms living in the mesenteric venous system. 
The parasite lays eggs in small vessels of the submucosa of the intestines. These eggs are transported by the blood 
flow to the liver and they cause a granulomatous inflammatory reaction (Oliveira et al., 2011). The tegument of the 
parasite contains some proteins that act as a barrier and, consequently, create a protection against the attack of the 
host’s immune system. The tegument has also the capacity of incorporating certain proteins found in the host trough 
a passive mechanism; thus, the parasite can be unobserved in the host’s immune system (Braschi & Wilson, 2006). 
About 740 proteins of the S. mansoni were identified, and they could be classified in three categories: (1) the 
tegument only, (2) the body of the parasite only, and (3) both the tegument and the body of the parasite. A total of 
222 proteins were found in the tegument (Braschi et al., 2006). The discovery of these specific proteins is of great 
interest for the scientific community because they are the first ones to be presented to the host’s immune system. For 
this reason, these proteins provide substantial elements for future studies that are centered on the development of 
vaccines (Verjovski-Almeida et al., 2003). The acute phase of the disease is quite debilitating for human beings. 
They present fever even before the eggs appear in the feces (Rabello, 1995). Plasma levels of the tumor necrosis 
factor (TNF) also occur. These levels increase because of the peripheral blood mononuclear cells (PBMCs). The 
production of cytokines by the PBMCs, after stimulation with the parasite’s antigens, reflects on a Th1 response. 
However, as the disease progresses, the antigens of the eggs induce aTh2 response (Montenegro et al., 1999). The 
most serious form of chronic schistosomiasis is caused by the hepatosplenomegaly, which is generally accompanied 
by severe hepatic fibrosis, periportal and portal hypertension (Dunne & Pearce, 1999). In the infected host, the 
disease is characterized by the presence of granuloma. The granuloma is formed by: several inflammatory cells of 
the immune system, components of the extracellular matrix, adhesion proteins, growth and angiogenesis factors. All 
of these elements are in the origin of a spherical structure that envelops each egg individually. After the death of the 
egg, the granuloma decreases and leaves in its place fibrous plaques that increase the portal blood pressure and the 
diameter of the portal vein (Lenzi et al., 2008; Pearce & Macdonald, 2002). This reaction shows the importance of 
the egg as a pathogenic agent; about half of the eggs produced by the worms reach the intestinal light and are 
eliminated by the feces (Rey, 2008). As a result of several granulomatous reactions in the liver, the functions of this 
organ are altered (Jankovic et al., 1997); therefore, such reactions can cause severe hepatic failures. The S. mansoni 
causes a low natural immunity and they are able to evade or resist to the specific immune responses of the hosts. The 
propagation of the disease is even more pronounced by the lack of infrastructure of water resources, deficiency in 
people’s education concerning the domestic and hygienic habits and absence of sanitary education (Filho & Silveira, 
2001). Given this, the study of the enzymes that participate in the S. mansoni essential pathways can be quite 
promising to develop specific tools to control this illness. The nucleotides of purines are required in all living beings 
to DNA and RNA synthesis. These nucleotides can be acquired by the de novo synthesis or by the salvage pathway 
of the purines. The de novo pathway uses simple precursors to the synthesis of several nucleotides. On the other 
hand, the salvage pathway of purines is the reutilization of pathways by which the organism can satisfy its 
requirement of pre-formed purines (el Kouni et al., 1987). One of the advantages of the salvage pathway is the fact 
that the de novo pathway demands a big quantity of energy to the purine bases (Voet & Voet, 1995).  Different from 
its human host, the S. mansoni depends entirely on the salvage pathway of purines to feed its demand of purine 
bases (Senft et al., 1972). Another relevant factor to this research is the fact that the literature does not have 
sufficient data to respond to the questions about the mechanisms of action of these enzymes. Such enzymes act in an 
intracellular manner, and no scientific works which can prove their exposition or secretion by the S. masoni have 
been found. Therefore, essential enzymes to the parasite can be promising study subjects. The enzymes 
hypoxanthine guanine phosphoribosyltransferase (HGPRT) (E.C 2.4.2.8), adenylate kinase (ADK) (E.C 2.7.4.3) and 
purine nucleoside phosphorilase (PNP) (EC 2.4.2.1), are cytoplasmic enzymes and its exposure in the adult worm’s 
tegument were not yet verified. Some studies which reports secretion of one of the enzymes component of the S. 
mansoni purine salvation pathway, the nucleoside-diphosphate kinase (NDPK), by prokaryote pathogens, as showed 
by Zaborina (1999) in which was observed secretion of this enzyme by Mycobacterium bovis e Pseudomonas 
aeruginosa bacteria, as well as Punj (2000). Recently a group of collaborators with this work (IFSC-USP) showed 
that the structures of the PNP1, HGPRT and ADK enzymes do not present any danger as for the immunization in 
human beings: the highest percentages of homology were between 30-50% of identity with the same in human 
beings. However, in order to occur an immunological response, it is fundamental to have some accessible factors 
(antigens exposed) and these external antigenic factors are the first to be recognized; with the time being, with the 
disruption of some of the antigens, more internal factors can be expressed or excrete physiologically. The innate 
immune system is able to identify antigenic parts present in the pathogen surfaces known as PAMPs (Pathogen-
Associated Molecular Pattern) and then the first patterns of immunological response against the pathogen is 
initiated. The pathogenesis of the schistosomiasis mansoni is dependent on the human interaction with the helminth, 
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being important factors: the strain, the evolutive phase, the intensity and the number of infections. The acute phase is 
divided in  pré-patent before the oviposition and the post-patent after the oviposition. Even though the 
immunological mechanisms involved in the response of the acute infection are not yet completely explained, some 
investigations in murine models indicated that there is in the beginning a predominance of an immune response type 
Th1, substituted by Th2 in the post-patent phase (Silva et al., 2008). In the pre-patent phase, plasmatic levels 
considered of tumor necrosis (TNF) and of Interleukins 2 and 6 produced by the mononuclear cells (Pearce & 
Macdonald, 2002). It is supposed that the immune response type Th1 is responsible for the damages in the tissues 
and the clinic manifestations in the acute phase. Another interesting factor is the cellular cytotoxicity dependent on 
the antibodies (ADCC), with effector action on schistosomula. Lately the Oswaldo Cruz Institute (IOC), located in 
Rio de Janeiro, Brazil, produced and patented the first vaccine to the schistosomiasis in the world. The vaccine, 
approved by the National Agency of Sanitary Supervision (ANVISA/Brazil), demonstrated to be safe and able to 
immunize human beings against the disease. The national dose was produced from an antigen Sm14, being part of 
the fatty acid-binding proteins (Tendler et al., 1995). In 2008, the RNAi technique reinforced the importance of the 
enzyme HGPRT to the survival of the parasite. Small RNAs of interference (RNAis) were produced against enzyme, 
injected after 70 days of infection with cercariae in mice. The number of worms was counted six days after the 
injection (Pereira et al., 2008). The work by Peng (2004) that demonstrated in serums of rabbits infected with 
cercarie Schistosoma japonicum a positive immune response with the enzyme adenylate kinase. Two kinds of 
pathways lead to nucleotide synthesis in the living beings: de novo and salvation pathways. The de novo pathways 
for purine and pyrimidine biosynthesis are similar in almost all living organism and have as metabolic precursors: 
amino acids, ribose 5- phosphate, CO2 e NH3 (Freeman, 2008). The salvation pathways are the reutilization of 
nucleosides that were released from the break of nucleic acids. Thus, one of the advantages of the salvation pathway 
is that it requires less amount of energy for purine bases synthesis, compared to the de novo pathway. In parasite 
have demonstrated a fast adenine incorporation in nucleotides and were not able to establish 14C-glycine and 14C-
glucose incorporation in the purine ring (Senft et al., 1972). This shows great dependence of an external supply of 
pre-formed bases for nucleotide synthesis, as shown by the loss of the purine synthesis of the de novo pathway. The 
HGPRT enzyme catalyzes the reversible phosphorylation from hypoxanthine and guanine to inosine monophosphate 
or guanosine monophosphate, respectively, and pyrophosphate using as phosphate and ribose donor the 5-
phosphoribosyl- diphosphate (PRPP). Researches on S. mansoni schistosomula indicates that organisms basically 
depends on the purine bases retrieval in order to ensure its purine nucleotide needs (Dovey et al., 1986). Due to 
limited interconversion between adenine and guanine nucleotides, the S. mansoni HGPRTase provides the main 
sources of guanine nucleotides for the parasite. The  enzyme has been found usually as a dimer in solution on 
Tritrichomonas foetus (HGXPRT) (Somoza et al., 1996). Trypanosoma brucei, Trypanosoma cruzi, Leishmania 
tarentolae (Monzani et al., 2002) and Leishmania donovani (Ullman et al., 1997) organisms. It is found in the 
tetramer form in solution on Toxoplasma gondii (HGXPRT) (Héroux et al., 1999), Escherichia coli (HPRT) (Gudatt 
et al., 2002). Plasmodium falciparum (HGXPRT) (Keough et al., 1999) and on human enzyme (Xu et al., 1997). 
This enzyme has 48% of identity, when compared to the human homolog and demonstrated several properties that 
distinguishes it from mammal’s enzymes (Dovey et al., 1986).  Three homologous genes for the HGPRT 
(Smp_148820, Smp_168500, Smp_103560) were found at the parasite’s genome, which are related with the 
parasite’s different life stages. The PNP is an enzyme that reversibly catalyzes the phosphorylase purine nucleoside 
in order to generate the purine base and ribose-1- phosphate and it has been descripted as participant in the S. 
mansoni salvation purine pathway with the sole purpose of supplying purine bases used in the DNA and RNA 
synthesis (Senft et al., 1972; Senft et al., 1983). It is important to notice that, in Schistosoma adult worms (Senft et 
al., 1983) and schistosomula (Dovey et al., 1984) unlike its mammal hosts, the parasite are not able to synthesize 
purine nucleosides and depend solely on the salvation pathway to its purine necessities. Two isoforms were 
identified in the parasite’s genome, named SmPNP1 e SmPNP2. The SmPNP1was the first salvation pathway 
enzyme which was cloned, expressed, purified, crystallized and had its structure resolved (Pereira et al., 2003; 
Pereira et al., 2005). The SmPNP1 has 287 amminoacids, being a trimer in solution and in crystal form.  The 
SmPNP2, which has 61,8% of identity, when compared to SmPNP1 and coded to a protein with 299 amminoacids, 
being greater than SmPNP1. Adenylate kinase (ADK) is an enzyme that is involved in cellular homeostasis, 
energetic metabolism and nucleotide synthesis. The enzyme catalyzes the ATP (Adenosine triphosphate) + AMP 
Adenosine monophosphate ƒ´ 2 ADP (Adenosine diphosphate) reaction. It is known that several ADK are found in 
mammals, as the skeletal muscle is particularly rich in ADK1, main provider of isoforme citosolica (Tanabe et al., 
1993). The ADK1 (Smp_071390) codes to a protein with 197 amminoacids and has 54% of identity, when 
compared to the human ADK1. The work of Peng (2004) has shown that immunization with the Schistosoma 
japonicum ADK enzyme induced the antibodies production against S. japonicum, revealing a positive immune 
response post-immunization. Thus, our study aimed to assess whether purine salvation pathway enzymes (PNP 1, 
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HGPRT and ADK), when used as immunizing, associated to the aluminum hydroxide adjuvant, stimulate a specific 
immune response which favors the S. mansoni antigens recognition. Hence, our work intends to assess whether S. 
mansoni PNP1, HGPRT and ADK  enzymes are able, futurely, to be candidates for a vaccine against this disease, 
since it has been demonstraded that these enzymes were able to produce an immunologic response after 
immunization in balb/c mice (Neris et al., 2013). Thereby, we suggest that these enzymes, by mechanisms yet 
unknown, seem to modulate the infection by Schistosoma in different species of rodents. These facts support the 
hypothesis that the proposed enzymes, although related to the DNA of the parasite, can be expressed in the S. 
mansoni membrane and excreted by some pathway, which can cause a specific activation during the schistosomiasis 
mansoni.  
 
2. Material and Methods 
 
2.1  The mice 
 
We used in this experiment female mice of Balb/c lineage and specific pathogen free (SPF). They weighed between 
15 and 18 grams, and they were brought from the CEMIB of the University of Campinas (UNICAMP), Brazil. The 
mice were kept in proper cages, with free access to potable water and standard commercial diet, in the vivarium of 
the Department of Morphology and Pathology of the University of São Carlos, Brazil. The procedures of this 
experiment were based upon the Ethical Principles of the Animal Experimentation, adopted by the Brazilian Society 
of Laboratory Animal Science (SBCAL), and they were submitted and approved by the Ethics Commission in 
Animal Experimentation (CEEA) of the University of São Carlos. 
 
2.2  Obtaining the Schistosoma mansoni cercariae and the infection of the mice  
 
The larvae (cercariae) of S. mansoni, strain LE (BH-MG), were gently given in by the Professor Vanderlei 
Rodrigues, member of the Department of Biochemistry and Immunology of the University of São Paulo- 
(FMRP/USP). This lineage is routinely maintained by passage through the Biomphalaria glabrata snails and the 
Swiss mice. Infected B. glabrata snails were induced to eliminate the cercariae by exposition to artificial elimination 
30º C in non-chlorine water bath during 1 hour. The mice were infected using subcutaneous route (s.c.) with 50 
cercariae of S. mansoni in 0,3 mL of physiological solution 0,9% NaCl/animal. This volume and this concentration 
(physiological solution) are unable to affect the viability of the cercariae. The method of infection was standardized 
by the laboratory technician Olinda Mara Brigoto of the Department of Biochemistry and Immunology of the 
University of São Paulo (FMRP/USP). 
 
2.3 Obtaining of  PNP1, HGPRT and ADK recombinant enzymes  
 
The methodology to obtain the PNP1 enzyme was done according to Pereira (2003), and for the HGPRT and ADK 
enzymes, according to Romanello (2011) The procedure was conducted at the Cristallography Laboratory of the São 
Carlos Institute of Physics – IFSC, located at University of São Paulo, Brazil – USP, São Carlos – SP – Brazil. The 
recombinant enzymes were synthesized by the insertion of plasmids in bacterial cultures. To do so, the protein 
expression methodology was used. The enzymes were purified through the method of affinity chromatography under 
the coordination of Dr. Humberto D’ Muniz Pereira and supervision of Prof. Dr. Richard C. Garratt, both belonging 
to the same aforementioned institution. 
 
2.4  Immunization of the mice with the recombinant enzymes 
 
After purification, 100µg individually, the recombinant enzymes PNP1, HGPRT and ADK were added to 200µL of 
sterile PBS, containing 100µg of aluminum hydroxide (dynamics 35044) and injected thrice into the mice through 
intraperitoneal route (i.p) in intervals of 15 days. After 15 days since last immunization, the mice were infected with 
50 cercariae/animal of S. mansoni. The experimental groups consisted of a control group of 6 mice, which did not 
receive any kind of immunization, a group which was infected only, and a group of 6 mice, which was immunized 
(PNP1 or HGPRT or ADK) and then infected. The model proposed in the experiment was repeated twice in order to 
confirm the results. The mice were euthanized on the 48
th 
and 85
th 
days after the infection with the Thionembutal 
anesthetic (North Chicago, Illinois, USA). The days to perform the euthanasia were established on the 48
th
 and 85
th
 
days due to the facts that the parasite had already started laying eggs and the disease had already reached its chronic 
phase, respectively.  
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2.5 Counting the eggs in the feces 
 
On the 47
th 
and 84
th 
days after the infection, the feces of the mice were collected and examined. For the analysis, we 
used the Kato-Katz kit (Katz & Peixoto, 2000). This kit, through the Helm Test, is developed by the 
Immunobiological Technology Institute (Biomanguinhos, Fiocruz – Brazil) and recommended by the World Health 
Organization because it increases from 2 to 4 times the chances of detecting the eggs of the helminths in the feces. 
The Kato-Katz method does not need water, light or any other accessory to prepare the blades, which can be 
conserved in room temperature for up to two years. The procedures for the analysis were executed following the 
manufacturer’s instructions. The feces were submitted to the sieving filter-Test, mounting on microscope slides and 
covered with cellophane cover slip pre-colored with malachite green pigment. After counting the eggs, we 
calculated the quantity of eggs in each gram of feces following the formula: nº of eggs of the sample = nº of eggs 
found in the blade X factor 24 (the factor varies depending on each Kit). The Kato-Katz kit was gently donated by 
the Osvaldo Cruz-Biomanguinhos Foundation, Rio de Janeiro-RJ (Brazil).  
 
2.6 Collecting adult worms from the hepatic portal system 
 
The adult worms were collected from the mice via perfusion of the hepatic portal system (obtained by section), with 
phosphate buffered saline 0,85% on the 48
th
 and 85
th
 days after the infection. The reduction percentage (%) of the 
parasitic charge was measured comparing the number of mated adult worms obtained in each experimental group 
and its corresponding control, (infected only), according to Fonseca’s formula (2004) GR=RGC – RGE x 100/RGC, 
in which GR is the degree of reduction, RGC is the number of worms collected from the control group, and RGE is 
the number of worms collected from the experimental group.   
 
2.7 Statistical analysis 
 
The results were expressed as means and standard deviations. Data from pairs of groups were analyzed using the 
Mann-Whitney U test; and data from multiple groups were analyzed using the ANOVA test followed by a multiple 
comparison test (Bonferroni’s Multiple Comparison Test) (Prism 5.0 software).  
 
3. Results 
 
3.1 Evaluation of eggs per gram of feces on the 47
th
 day after infection 
 
 In figure 1, the immunized with PNP1 enzyme/infected group presented significant decrease in the number of eggs 
per gram of feces when compared with the infected only group. Also the immunized with HGPRT enzyme/infected 
group showed significant decrease of eggs per gram of feces when compared with the infected only group. The 
immunized with ADK enzyme/infected group showed a non-significant decrease of eggs per gram of feces 
compared with the infected only group. 
 
3.2   Number of  mated adult worms recovered on the 48
th
 day after infection 
 
 The mated adult worms recovered from groups: only infected, immunized with PNP1 enzyme/infected, immunized 
with HGPRT enzyme/infected and immunized with ADK enzyme/infected are depicted in figure 2, along with their 
respective percentages ( % ) of reduction of parasite load , calculated according to Fonseca et al., 2004. The average 
number of mated adult worms recovered from the infected group was 85, whereas the immunized with PNP1 
enzyme/infected group presented an average number of 72. As for the immunized with HGPRT enzyme/infected 
group, the average number of mated worms was 62, and 77 for the immunized with ADK enzyme/infected group. 
The percentage reduction in the parasite load in the group of animals immunized with PNP1 enzyme /infected group 
was of 25%, if compared to the infected only group, whereas the group of animals immunized with HGPRT 
enzyme/infected showed a percentage reduction of 27 % of parasite load, if compared to the infected only group. In 
the group of animals immunized with ADK enzyme/infected, the percentage of reduction was 9,41 % over the 
infected only group.  
 
3.3 Evaluation of eggs per gram of feces on the 84
th
 day after infection 
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In figure 3, the immunized with the PNP1 and HGPRT enzymes/infected groups showed a non-significant decrease 
of eggs per gram of feces, compared with the infected only group. 
 
3.4  Number of  mated adult worms recovered on the 85
th
 day after infection 
 
The mated adult worms recovered from groups: only infected, immunized with PNP1 enzyme/infected, immunized 
with HGPRT enzyme/infected and immunized with ADK enzyme/infected are depicted in figure 4, along with their 
respective percentages (%) of reduction of parasite load , calculated according to Fonseca et al., 2004. The average 
number of mated adult worms recovered from the infected group was 92, whereas the immunized with PNP1 
enzyme/infected group presented an average number of 49. As for the immunized with HGPRT enzyme/infected 
group, the average number of mated worms was 71, and 67 for the immunized with ADK enzyme/infected group. 
The percentage reduction in the parasite load in the group of animals immunized with PNP1 enzyme /infected group 
was of 50%, if compared to the infected only group, whereas the group of animals immunized with HGPRT 
enzyme/infected showed a percentage reduction of 19 % of parasite load, if compared to the infected only group. In 
the group of animals immunized with ADK enzyme/infected, the percentage of reduction was 27 % over the 
infected only group.  
 
4. Dicussion 
 
 Schistosomiasis, a disease caused by the trematodes of the Schistosoma genus, affects about 240 million people 
worldwide. Even though the existence of drugs against adult worms, there is deficiency of drugs which can control 
the morbid effects of infection or even vaccines which can control the parasite’s dissemination. Although the Health 
Ministry has made available a vaccine for tests in humans, in 2012, its efficiency is still debatable. During infection, 
the immune response of the host against cercariae and schistosomules is initially mediated by Th1 cells. With the 
spread of infection, response is modulated by Th2 cells induced particularly during the formation of granulomas 
generated by egg antigens retained in the tissues of the host. (McManus & Loukas, 2008). The PZQ is currently the 
only effective drug against all Schistosomas (WHO, 2012) and its use in populations has presented some problems 
such as reduction of therapeutic efficacy in patients from different regions such as Senegal and Egypt. (Gryseels et 
al., 2001; Ismail et al., 1999). Thus, the search for new therapeutic tools is necessary, such as effective ways of 
immunization. The main characteristic of an ideal vaccine for schistosomiasis is the ability to decrease the parasite 
load, being the migrating schistosomula the main target (Wilson & Coulson, 2006). However, in the case of 
schistosomiasis mansoni, the complexity of the parasite’s life cycle within its hosts, as well as the variety of immune 
responses induced by them, hampers the development of an effective vaccine (Dupre et al., 2001).  The mated adult 
worms of S. mansoni live in the venules of the hemorrhoidal plexus and the portal system, (Henri et al., 2002) and in 
these locations, females make oviposition of around 300 eggs per day and approximately 20% of them go toward the 
intestinal lumen, while the rest is mostly stuck in the intestine, spleen and liver of the host, causing inflammatory 
reactions. (Lenzi et al., 1987). This inflammatory process, triggered mainly by 2antigens released from eggs, 
promotes increased cellular infiltration, directing inflammatory cells to form granulomas around eggs trapped in the 
tissues.  The decrease in the number of eggs is very important, as the granulomas are caused mainly by immune 
responses against soluble egg antigens (SEAs) and also because a lesser number of eggs being deposited in tissues 
can cause a reduction of granuloma (Helmy et al., 2009), causing a possible morbidity reduction of this 
pathogenesis. Thus, our results showed, on the 47th day after infection, a significant reduction in the number of eggs 
per gram of feces of animals which were immunized/infected with the PNP1 and HGPRT enzymes (Fig. 1), 
suggesting that these enzymes can interfere with the process of oviposition by females or be related to the reduction 
of adult worms. The activation of the immune response during infection may favor the control of the infectious 
agent. Therefore, it is of great value to note whether the modulation of immunological parameters interfere in the 
infectious process, such as by analysis of parasite load and of the cellular profile involved in the inflammatory 
process triggered during infection. In the work of Neris  (2013) it was demonstrated that the cited enzymes are able 
to stimulate the production of immunoglobulins of the IgG, IgG2a and IgE classes. Our results showed that at 48th 
and 85th days after infection, all groups which were immunized with the studied enzymes showed a reduction in 
parasite load (Fig. 2 and 4). Therefore, our results corroborate with other studies which used different proteins of S. 
mansoni through immunization in animal models, yielding promising results. (Matsumoto, et al.,1988; Pearce et 
al.,1988; Correa-Oliveira et al., 1989; Moser, et al., 1991; Porchet et al., 1994; Da’Dara, et al., 2001; AL-sherbiny et 
al., 2003; Varaldo et al., 2004; Fonseca,et al., 2005). It is observed that our immunization with the enzymes 
promoted a possible immunoreactivity, favoring the reduction of parasitic load. In face of these facts, emerged the 
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hypothesis that the proposed enzymes, despite being related to the parasite’s DNA, can be expressed in the S. 
mansoni membrane and secreted by some pathway. It is necessary, however, further studies in order to fully 
comprehend the immune mechanism from the mentioned enzymes in this experimental model. 
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Figure 1 - Number of eggs per gram of feces on the 47
th
 day after infection. Data represent mean ± EPM (n= 10 
animals) of 2 independent experiments. The symbol * (p < 0,05) represents a significant difference between the 
results obtained from the immunized/infected groups when compared to the infected group, using the nonparametric 
one-way ANOVA Tukey's test.  
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Figure 2. Number of  mated adult worms recovered in each group, along with their respective percentages ( 
% ) of reduction of parasite 48
th
 day after infection. Data represent mean ± EPM (n= 10 animals) of 2 
independent experiments, using the nonparametric one-way ANOVA Tukey's test.  
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Figure 3. - Number of eggs per gram of feces on the 84
th
 day after infection.  
Data represent mean ± EPM (n= 10 animals) of 2 independent experiments, using the nonparametric one-way 
ANOVA Tukey's test.  
ISSN 2320-5407                             International Journal of Advanced Research (2013), Volume 1, Issue 10, 894-905 
 
901 
 
  
0
5
10
15
Infected only
PNP1/Infected
HGPRT/Infected
ADK/Infected
50%
19%
27%
85th day post-infectionN
u
m
b
e
r 
o
f 
 m
a
te
d
 a
d
u
lt
 w
o
rm
s
 r
e
c
o
v
e
re
d
 
Figure 4. Number of  mated adult worms recovered in each group, along with their respective percentages 
(%) of reduction of parasite 85
th
 day after infection. Data represent mean ± EPM (n= 10 animals) of 2 
independent experiments, using the nonparametric one-way ANOVA Tukey's test. 
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